Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Canaccord lowered the firm’s price target on Sage Therapeutics (SAGE) to $8 from $9 and keeps a Hold rating on the shares. The firm said they ...

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago. These ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of shareholders.

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a ...